Therefore, the targeted modulation of PPARγ or C/EBPβ may potentially offer a viable therapeutic strategy for ameliorating inflammation in individuals suffering from ALI and ARDS. This evidence concerns the gene CEBPB and acute respiratory distress syndrome.